NASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis $0.87 +0.00 (+0.03%) (As of 10:53 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Equillium Stock (NASDAQ:EQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Equillium alerts:Sign Up Key Stats Today's Range$0.84▼$0.8850-Day Range$0.64▼$1.1352-Week Range$0.45▼$3.25Volume16,690 shsAverage Volume270,755 shsMarket Capitalization$30.50 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Read More… CRUSHED: How Biden's Replacement Will Devastate Your 401(k)! (Ad)Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << Equillium Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreEQ MarketRank™: Equillium scored higher than 52% of companies evaluated by MarketBeat, and ranked 549th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEquillium has only been the subject of 1 research reports in the past 90 days.Read more about Equillium's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from ($0.14) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Equillium's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 13.77%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.88% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 13.77%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Equillium this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EQ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,785.00 in company stock.Percentage Held by Insiders30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.05% of the stock of Equillium is held by institutions.Read more about Equillium's insider trading history. Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Email Address EQ Stock News HeadlinesPenny Tom Sells 38,806 Shares of Equillium, Inc. (NASDAQ:EQ) StockSeptember 18, 2024 | insidertrades.comEquillium (NASDAQ:EQ) Stock Quotes, Forecast and News SummaryOctober 4 at 5:46 AM | benzinga.comWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.October 7, 2024 | Angel Publishing (Ad)Equillium collaborates with Vivtex for oral formulation of autoimmune therapySeptember 17, 2024 | msn.comEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitSeptember 10, 2024 | finance.yahoo.comEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceAugust 28, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)August 19, 2024 | markets.businessinsider.comEquillium Second Quarter 2024 Earnings: Beats ExpectationsAugust 11, 2024 | finance.yahoo.comSee More Headlines EQ Stock Analysis - Frequently Asked Questions How have EQ shares performed this year? Equillium's stock was trading at $0.7230 at the start of the year. Since then, EQ shares have increased by 22.3% and is now trading at $0.8841. View the best growth stocks for 2024 here. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) posted its quarterly earnings results on Thursday, August, 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.16. The business had revenue of $13.85 million for the quarter, compared to analyst estimates of $8.15 million. Equillium had a negative net margin of 19.51% and a negative trailing twelve-month return on equity of 36.88%. When did Equillium IPO? Equillium (EQ) raised $70 million in an initial public offering (IPO) on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel acted as the underwriters for the IPO. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today10/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EQ CUSIPN/A CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+465.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,340,000.00 Net Margins-19.51% Pretax Margin-18.31% Return on Equity-36.88% Return on Assets-17.31% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual Sales$42.62 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.38Miscellaneous Outstanding Shares35,255,000Free Float24,573,000Market Cap$31.17 million OptionableNot Optionable Beta1.83 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:EQ) was last updated on 10/7/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredStrikes and Economic Unrest: Are You Prepared for What’s Coming?The rapid advancement of artificial intelligence and automation is reshaping industries and posing threats to ...InvestorPlace | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredAI Detects Profit Surge On MondayThis has given investors the opportunity to beat the market by 1,700% and a 100% win rate to begin the year.Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.